Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors

被引:62
|
作者
Doll, Margaret K. [1 ]
Pettigrew, Stacy M. [1 ]
Ma, Julia [2 ]
Verma, Aman [2 ,3 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Dept Populat Hlth Sci, Albany, NY 12208 USA
[2] Precis Analyt, Montreal, PQ, Canada
[3] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
关键词
test; negative; vaccine effectiveness; COVID-19; influenza; SARS-CoV-2; VARIANT PREDOMINANCE; SELECTION; DELTA;
D O I
10.1093/cid/ciac234
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Correlated influenza and coronavirus disease 2019 (COVID-19) vaccination behaviors can bias influenza and COVID-19 vaccine effectiveness (VE) estimates from test-negative studies. Bias depends upon the proportion of controls with the other vaccine-preventable disease, correlation between vaccines, and true VE of both vaccines. Background The test-negative design is commonly used to estimate influenza and coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE). In these studies, correlated COVID-19 and influenza vaccine behaviors may introduce a confounding bias where controls are included with the other vaccine-preventable acute respiratory illness (ARI). We quantified the impact of this bias on VE estimates in studies where this bias is not addressed. Methods We simulated study populations under varying vaccination probabilities, COVID-19 VE, influenza VE, and proportions of controls included with the other vaccine-preventable ARI. Mean bias was calculated as the difference between estimated and true VE. Absolute mean bias in VE estimates was classified as low (<10%), moderate (10% to <20%), and high (>= 20%). Results Where vaccination probabilities are positively correlated, COVID-19 and influenza VE test-negative studies with influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ARI controls, respectively, underestimate VE. For COVID-19 VE studies, mean bias was low for all scenarios where influenza represented <= 25% of controls. For influenza VE studies, mean bias was low for all scenarios where SARS-CoV-2 represented <= 10% of controls. Although bias was driven by the conditional probability of vaccination, low VE of the vaccine of interest and high VE of the confounding vaccine increase its magnitude. Conclusions Where a low percentage of controls is included with the other vaccine-preventable ARI, bias in COVID-19 and influenza VE estimates is low. However, influenza VE estimates are likely more susceptible to bias. Researchers should consider potential bias and its implications in their respective study settings to make informed methodological decisions in test-negative VE studies.
引用
收藏
页码:E564 / E571
页数:8
相关论文
共 50 条
  • [21] Resolution of coronavirus disease 2019 (COVID-19)
    Habas, Khaled
    Nganwuchu, Chioma
    Shahzad, Fanila
    Gopalan, Rajendran
    Haque, Mainul
    Rahman, Sayeeda
    Majumder, Anwarul Azim
    Nasim, Talat
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (12) : 1201 - 1211
  • [22] Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study
    Zanettini, Claudio
    Omar, Mohamed
    Dinalankara, Wikum
    Imada, Eddie Luidy
    Colantuoni, Elizabeth
    Parmigiani, Giovanni
    Marchionni, Luigi
    VACCINES, 2021, 9 (05)
  • [23] The Coronavirus Disease 2019 (COVID-19) Pandemic
    Baloch, Saira
    Baloch, Mohsin Ali
    Zheng, Tianli
    Pei, Xiaofang
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 250 (04) : 271 - 278
  • [24] The management of coronavirus disease 2019 (COVID-19)
    Liu, Jialin
    Liu, Siru
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (09) : 1484 - 1490
  • [25] Estimands and Estimation of COVID-19 Vaccine Effectiveness Under the Test-Negative Design Connections to Causal Inference
    Schnitzer, Mireille E.
    EPIDEMIOLOGY, 2022, 33 (03) : 325 - 333
  • [26] The Willingness to Pay for a Hypothetical Vaccine for the Coronavirus Disease 2019 (COVID-19)
    Tsutsui, Yoshiro
    Shahrabani, Shosh
    Yamamura, Eiji
    Hayashi, Ryohei
    Kohsaka, Youki
    Ohtake, Fumio
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (23)
  • [27] Treatment for Immune Thrombocytopenia in Coronavirus Disease 2019 (COVID-19) Infection after COVID-19 Vaccination: A Case Report
    Lee, Jun Hee
    Oh, Sang -Min
    Lee, Eunyoung
    Bang, Ji Hwan
    Park, Sang -Won
    INFECTION AND CHEMOTHERAPY, 2022, 54 (03) : 559 - 562
  • [28] Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis
    Eiberg, Mads Frederik
    Rezahosseini, Omid
    Bukan, Katrine Brandt
    Arp, Bodil Charlotte
    Le, Vivian Bui
    Ahmad, Faiza
    Howitz, Michael
    Lendorf, Maria
    Friborg, Jeppe
    Lindegaard, Birgitte
    Harboe, Zitta Barrella
    VACCINE, 2024, 42 (20)
  • [29] Predictors of seasonal influenza and COVID-19 vaccination coverage among adults in Tennessee during the COVID-19 pandemic
    Cunningham-Erves, J.
    George, W.
    Sanderson, M.
    Stewart, E.
    Jin, S. W.
    Davis, J.
    Brandt, H. M.
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [30] Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers
    Patel, Ursula C.
    Schultz, Thomas
    Schmidt, Justin
    VACCINE, 2023, 41 (33) : 4782 - 4786